Edina Wang

Edina Wang is a Researcher affiliated with the UWA Medical School at the University of Western Australia, based at the UWA Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research). Her work focuses on epigenetic editing, CRISPR technology, nanoparticle drug delivery, and oncogene signaling in breast cancer. She has contributed to over 15 peer-reviewed publications and leads or co-leads multiple grants targeting breast cancer therapies and molecular mechanisms.

• Education: Details not explicitly stated in text, but her research indicates expertise in molecular biology and drug delivery systems.

Her research interests include synthetic epigenetic reprogramming, CRISPR-based therapies for solid tumors, and the development of novel therapeutic strategies for triple-negative breast cancer. She explores marine-derived anticancer compounds and peptide-based drug delivery systems. Her work intersects nanotechnology, molecular biology, and clinical oncology.

Recent articles highlight advancements in lipid nanoparticle-mediated CRISPR delivery for epigenetic editing and the use of synthetic peptides to inhibit oncogenic pathways. Her projects include therapeutic targeting of Rab12 tumor suppressors and PI3K-AKT-mTOR signaling pathways in breast cancer.

• Grants: Active projects include 'Therapeutic opportunities for metastatic breast cancer' and 'Targeting an alternate nuclear receptor for aggressive breast cancers.'
• Labs/Teams: Affiliated with the Harry Perkins Institute of Medical Research and collaborates on interdisciplinary teams focusing on nanomedicine and epigenetic therapies.